Read the full stored bill text
SECOND REGULAR SESSION
SENATE BILL NO. 1605
103RD GENERAL ASSEMBLY
INTRODUCED BY SENATOR HENDERSON.
6874S.01I KRISTINA MARTIN, Secretary
AN ACT
To repeal section 195.017, RSMo, and to enact in lieu thereof one new section relating to 7 -
hydroxymitragynine.
Be it enacted by the General Assembly of the State of Missouri, as follows:
Section A. Section 195.017, RSMo, is repealed and one new 1
section enacted in lieu thereof, to be known as section 195.017, 2
to read as follows:3
195.017. 1. The department of health and senior 1
services shall place a substance in Schedule I if it finds 2
that the substance: 3
(1) Has high potential for abuse; and 4
(2) Has no accepted medical use in treatment in the 5
United States or lacks accepted safety for use in treatment 6
under medical supervision. 7
2. Schedule I: 8
(1) The controlled substances listed in this 9
subsection are included in Schedule I; 10
(2) Any of the following opiates, including their 11
isomers, esters, ethers, salts, and salts of isomers, 12
esters, and ethers, unless specifically excepted, whenever 13
the existence of these isomers, esters, ethers and salts is 14
possible within the specific chemical designation: 15
(a) Acetyl-alpha-methylfentanyl (N-(1-(1-methyl-2- 16
phenethyl)-4-piperidinyl)-N-phenylacetamide); 17
SB 1605 2
(b) Acetylmethadol; 18
(c) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N- 19
phenylacetamide); 20
(d) Acryl fentanyl (-(1-phenethylpiperidin-4-yl)-N- 21
phenylacrylamide); 22
(e) AH-7921(3,4-dichloro-N-[(1-dimethylamino) 23
cyclohexylmethyl] benzamide); 24
(f) Allylprodine; 25
(g) Alphacetylmethadol (except levoalphacetylmethadol, 26
also known as levo-alpha-acetylmethadol levothadyl acetate 27
or LAAM); 28
(h) Alphameprodine; 29
(i) Alphamethadol; 30
(j) Alpha-methylfentanyl (N-1-(alphamethyl-beta- 31
phenyl) ethyl-4-piperidyl) propionanilide; 1-(1-methyl-2- 32
phenylethyl)-4 ((N-propanilido) piperidine); 33
(k) Alpha-methylthiofentanyl (N-(1-methyl-2-(2- 34
thienyl) ethyl-4-piperidinyl)-N-phenylpropanamide); 35
(l) Benzethidine; 36
(m) Betacetylmethadol; 37
(n) Beta-hydroxyfentanyl (N-(1-(2-hydroxy-2-phenethyl)- 38
4-piperidinyl)-N-phenylpropanamide); 39
(o) Beta-hydroxy-3-methylfentanyl (N-(1-(2-hydroxy-2- 40
phenethyl)-3-methyl-4-piperidinyl)-N-phenylpropanamide); 41
(p) Betameprodine; 42
(q) Betamethadol; 43
(r) Betaprodine; 44
(s) Clonitazene; 45
(t) Dextromoramide; 46
(u) Diampromide; 47
(v) Cyclopropyl fentanyl; 48
(w) Diethylthiambutene; 49
SB 1605 3
(x) Difenoxin; 50
(y) Dimenoxadol; 51
(z) Dimepheptanol; 52
(aa) Dimethylthiambutene; 53
(bb) Dioxaphetyl butyrate; 54
(cc) Dipipanone; 55
(dd) Ethylmethylthiambutene; 56
(ee) Etonitazene; 57
(ff) Etoxeridine; 58
(gg) 4-fluoroisobutyryl fentanyl -(4-fluorophenyl)-N- 59
(1-phenethylpiperidin-4-yl)isobutyramide; 60
(hh) Furanyl fentanyl -(1-phenethylpiperidin-4-yl)-N- 61
phenylfuran-2-carboxamide; 62
(ii) Furethidine; 63
(jj) Hydroxypethidine; 64
(kk) Ketobemidone; 65
(ll) Levomoramide; 66
(mm) Levophenacylmorphan; 67
(nn) 3-Methylfentanyl (N-(3-methyl-1-(2-phenylethyl)-4- 68
piperidyl)-N-phenylproanamide), its optical and geometric 69
isomers, salts, and salts of isomers; 70
(oo) 3-Methylthiofentanyl (N-((3-methyl-1-(2- 71
thienyl)ethyl-4-piperidinyl)-N-phenylpropanamide); 72
(pp) Methoxyacetyl fentanyl (2-methoxy-N-(1- 73
phenethylpiperidin-4-yl)-N-phenylacetamide); 74
(qq) Morpheridine; 75
(rr) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine); 76
(ss) MT-45(1-cyclohexyl-4-(1,2-diphenylethyl) 77
piperazine); 78
(tt) Noracymethadol; 79
(uu) Norlevorphanol; 80
(vv) Normethadone; 81
SB 1605 4
(ww) Norpipanone; 82
(xx) Ocfentanil N-(2-fluorophenyl)-2-methoxy-N-(1- 83
phenethylpiperidin-4-yl)acetamide; 84
(yy) Ortho-fluorofentanyl (N-2-(1-phenethylpiperidin- 85
yl)propionamide); other name 2-fluorofentanyl; 86
(zz) para-fluorobutyryl fentanyl (N-4-fluorophenyl)-N- 87
(1-phenethylpiperidin-4-yl)butyramide; 88
(aaa) Para-fluorofentanyl (N-(4-fluorophenyl)-N-(1-(2- 89
phenethyl)-4-piperidinyl) propanamide; 90
(bbb) PEPAP (1-(2-phenethyl)-4-phenyl-4- 91
acetoxypiperidine); 92
(ccc) Phenadoxone; 93
(ddd) Phenampromide; 94
(eee) Phenomorphan; 95
(fff) Phenoperidine; 96
(ggg) Piritramide; 97
(hhh) Proheptazine; 98
(iii) Properidine; 99
(jjj) Propiram; 100
(kkk) Racemoramide; 101
(lll) Tetrahydrofuranyl fentanyl (N-(1- 102
phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2- 103
carboxamide); 104
(mmm) Thiofentanyl (-phenyl-N-(1-(2-thienyl)ethyl-4- 105
piperidinyl)-propanamide; 106
(nnn) Tilidine; 107
(ooo) Trimeperidine; 108
(3) Any of the following opium derivatives, their 109
salts, isomers and salts of isomers unless specifically 110
excepted, whenever the existence of these salts, isomers and 111
salts of isomers is possible within the specific chemical 112
designation: 113
SB 1605 5
(a) Acetorphine; 114
(b) Acetyldihydrocodeine; 115
(c) Benzylmorphine; 116
(d) Codeine methylbromide; 117
(e) Codeine-N-Oxide; 118
(f) Cyprenorphine; 119
(g) Desomorphine; 120
(h) Dihydromorphine; 121
(i) Drotebanol; 122
(j) Etorphine (except hydrochloride salt); 123
(k) Heroin; 124
(l) Hydromorphinol; 125
(m) Methyldesorphine; 126
(n) Methyldihydromorphine; 127
(o) Morphine methylbromide; 128
(p) Morphine methylsulfonate; 129
(q) Morphine-N-Oxide; 130
(r) Myrophine; 131
(s) Nicocodeine; 132
(t) Nicomorphine; 133
(u) Normorphine; 134
(v) Pholcodine; 135
(w) Thebacon; 136
(4) Any of the following opiate similar synthetic 137
substances scheduled by the U.S. Drug Enforcement 138
Administration as substances that share a pharmacological 139
profile similar to fentanyl, morphine, and other synthetic 140
opioids, unless specifically excepted or unless listed in 141
another schedule: 142
(a) Butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N- 143
phenylbutyramide); 144
SB 1605 6
(b) U-47700 (3,4-Dichloro-N-[2-(dimethylamino) 145
cyclohexyl]--methyl benzamide). 146
(5) Any material, compound, mixture or preparation 147
which contains any quantity of the following hallucinogenic 148
substances, their salts, isomers and salts of isomers, 149
unless specifically excepted, whenever the existence of 150
these salts, isomers, and salts of isomers is possible 151
within the specific chemical designation: 152
(a) Alpha-ethyltryptamine; 153
(b) 4-bromo-2,5-dimethoxyamphetamine; 154
(c) 4-bromo-2,5-dimethoxyphenethylamine; 155
(d) 2,5-dimethoxyamphetamine; 156
(e) 2,5-dimethoxy-4-ethylamphetamine; 157
(f) 2,5-dimethoxy-4-(n)-propylthiophenethylamine; 158
(g) 2-(2,5-Dimethoxy-4-(n)-propylphenyl) ethanamine; 159
(h) 2-(2,5-Dimethoxy-4-ethylphenyl) ethanamine; 160
(i) 2-(2,5-Dimethoxy-4-methylphenyl) ethanamine; 161
(j) 2-(2,5-Dimethoxy-4-nitro-phenyl) ethanamine; 162
(k) 2-(2,5-Dimethoxyphenyl) ethanamine; 163
(l) 2-(4-Chloro-2,5-dimethoxyphenyl) ethanamine; 164
(m) 2-(4-Ethylthio-2,5-dimethoxyphenyl) ethanamine; 165
(n) 2-(4-Iodo-2,5-dimethoxyphenyl) ethanamine; 166
(o) 2-(4-Isopropylthio)-2,5-dimethoxyphenyl) 167
ethanamine; 168
(p) 4-methoxyamphetamine; 169
(q) 5-methoxy-3,4-methylenedioxyamphetamine; 170
(r) 4-methyl-2, 5-dimethoxyamphetamine; 171
(s) 3,4-methylenedioxyamphetamine; 172
(t) 3,4-methylenedioxymethamphetamine; 173
(u) 3,4-methylenedioxy-N-ethylamphetamine; 174
(v) N-hydroxy-3, 4-methylenedioxyamphetamine; 175
(w) 3,4,5-trimethoxyamphetamine; 176
SB 1605 7
(x) 5-MeO-DMT or 5-methoxy-N,N-dimethyltryptamine; 177
(y) Alpha-methyltryptamine; 178
(z) Bufotenine; 179
(aa) Diethyltryptamine; 180
(bb) Dimethyltryptamine; 181
(cc) 5-methoxy-N,N-diisopropyltryptamine; 182
(dd) Ibogaine; 183
(ee) Lysergic acid diethylamide; 184
(ff) Marijuana or marihuana, except industrial hemp; 185
(gg) Mescaline; 186
(hh) Parahexyl; 187
(ii) Peyote, to include all parts of the plant 188
presently classified botanically as Lophophora williamsii 189
Lemaire, whether growing or not; the seeds thereof; any 190
extract from any part of such plant; and every compound, 191
manufacture, salt, derivative, mixture or preparation of the 192
plant, its seed or extracts; 193
(jj) N-ethyl-3-piperidyl benzilate; 194
(kk) N-methyl-3-piperidyl benzilate; 195
(ll) Psilocybin; 196
(mm) Psilocyn; 197
(nn) Tetrahydrocannabinols naturally contained in a 198
plant of the genus Cannabis (cannabis plant), except 199
industrial hemp, as well as synthetic equivalents of the 200
substances contained in the cannabis plant, or in the 201
resinous extractives of such plant, or synthetic substances, 202
derivatives and their isomers, or both, with similar 203
chemical structure and pharmacological activity to those 204
substances contained in the plant, such as the following: 205
a. 1 cis or trans tetrahydrocannabinol and their 206
optical isomers; 207
SB 1605 8
b. 6 cis or trans tetrahydrocannabinol and their 208
optical isomers; 209
c. 3,4 cis or trans tetrahydrocannabinol and their 210
optical isomers; 211
d. Any compounds of these structures, regardless of 212
numerical designation of atomic positions covered; 213
(oo) Ethylamine analog of phencyclidine; 214
(pp) Pyrrolidine analog of phencyclidine; 215
(qq) Thiophene analog of phencyclidine; 216
(rr) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine; 217
(ss) Salvia divinorum; 218
(tt) Salvinorin A; 219
(uu) Synthetic cannabinoids: 220
a. Any compound structurally derived from 3-(1- 221
naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane by 222
substitution at the nitrogen atom of the indole ring by 223
alkyl, haloalkyl, alkenyl, cycloalkylmethyl, 224
cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4- 225
morpholinyl)ethyl group, whether or not further substituted 226
in the indole ring to any extent, whether or not substituted 227
in the naphthyl ring to any extent. Including, but not 228
limited to: 229
(i) AM2201, or 1-(5-fluoropentyl)-3-(1- 230
naphthoyl)indole; 231
(ii) JWH-007, or 1-pentyl-2-methyl-3-(1- 232
naphthoyl)indole; 233
(iii) JWH-015, or 1-propyl-2-methyl-3-(1- 234
naphthoyl)indole; 235
(iv) JWH-018, or 1-pentyl-3-(1-naphthoyl)indole; 236
(v) JWH-019, or 1-hexyl-3-(1-naphthoyl)indole; 237
(vi) JWH-073, or 1-butyl-3-(1-naphthoyl)indole; 238
SB 1605 9
(vii) JWH-081, or 1-pentyl-3-(4-methoxy-1- 239
naphthoyl)indole; 240
(viii) JWH-098, or 1-pentyl-2-methyl-3-(4-methoxy-1- 241
naphthoyl)indole; 242
(ix) JWH-122, or 1-pentyl-3-(4-methyl-1- 243
naphthoyl)indole; 244
(x) JWH-164, or 1-pentyl-3-(7-methoxy-1- 245
naphthoyl)indole; 246
(xi) JWH-200, or 1-(2-(4-(morpholinyl)ethyl))-3-(1- 247
naphthoyl)indole; 248
(xii) JWH-210, or 1-pentyl-3-(4-ethyl-1- 249
naphthoyl)indole; 250
(xiii) JWH-398, or 1-pentyl-3-(4-chloro-1- 251
naphthoyl)indole; 252
b. Any compound structurally derived from 3-(1- 253
naphthoyl)pyrrole by substitution at the nitrogen atom of 254
the pyrrole ring by alkyl, haloalkyl, alkenyl, 255
cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- 256
piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether 257
or not further substituted in the pyrrole ring to any 258
extent, whether or not substituted in the naphthyl ring to 259
any extent; 260
c. Any compound structurally derived from 1-(1- 261
naphthylmethyl)indene by substitution at the 3-position of 262
the indene ring by alkyl, haloalkyl, alkenyl, 263
cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- 264
piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether 265
or not further substituted in the indene ring to any extent, 266
whether or not substituted in the naphthyl ring to any 267
extent; 268
d. Any compound structurally derived from 3- 269
phenylacetylindole by substitution at the nitrogen atom of 270
SB 1605 10
the indole ring with alkyl, haloalkyl, alkenyl, 271
cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- 272
piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether 273
or not further substituted in the indole ring to any extent, 274
whether or not substituted in the phenyl ring to any 275
extent. Including, but not limited to: 276
(i) JWH-201, or 1-pentyl-3-(4- 277
methoxyphenylacetyl)indole; 278
(ii) JWH-203, or 1-pentyl-3-(2- 279
chlorophenylacetyl)indole; 280
(iii) JWH-250, or 1-pentyl-3-(2- 281
methoxyphenylacetyl)indole; 282
(iv) JWH-251, or 1-pentyl-3-(2- 283
methylphenylacetyl)indole; 284
(v) RCS-8, or 1-(2-cyclohexylethyl)-3-(2- 285
methoxyphenylacetyl)indole; 286
e. Any compound structurally derived from 2-(3- 287
hydroxycyclohexyl)phenol by substitution at the 5-position 288
of the phenolic ring by alkyl, haloalkyl, alkenyl, 289
cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2- 290
piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether 291
or not substituted in the cyclohexyl ring to any extent. 292
Including, but not limited to CP 47, 497 and homologues, or 293
2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2- 294
yl)phenol, where side chain n=5, and homologues where side 295
chain n-4,6, or 7; 296
f. Any compound containing a 3-(benzoyl)indole 297
structure with substitution at the nitrogen atom of the 298
indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, 299
cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4- 300
morpholinyl)ethyl group, whether or not further substituted 301
in the indole ring to any extent and whether or not 302
SB 1605 11
substituted in the phenyl ring to any extent. Including, 303
but not limited to: 304
(i) AM-694, or 1-(5-fluoropentyl)-3-(2- 305
iodobenzoyl)indole; 306
(ii) RCS-4, or 1-pentyl-3-(4-methoxybenzoyl)indole (SR- 307
19 and RCS-4); 308
g. CP 50,556-1, or [(6S,6aR,9R,10aR)-9-hydroxy-6- 309
methyl-3-[(2R)-5-phenylpentan-2-yl] oxy-5,6,6a,7,8,9,10,10a- 310
octahydrophenanthridin-1-yl] acetate; 311
h. HU-210, or (6aR,10aR)-9-(hydroxymethyl)-6,6- 312
dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- 313
tetrahydrobenzo[c]chromen-1-ol; 314
i. HU-211, or Dexanabinol,(6aS,10aS)-9-(hydroxymethyl)- 315
6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- 316
tetrahydrobenzo[c]chromen-1-ol; 317
j. Dimethylheptylpyran, or DMHP; 318
(6) Any material, compound, mixture or preparation 319
containing any quantity of the following substances having a 320
depressant effect on the central nervous system, including 321
their salts, isomers and salts of isomers whenever the 322
existence of these salts, isomers and salts of isomers is 323
possible within the specific chemical designation: 324
(a) Gamma-hydroxybutyric acid; 325
(b) Mecloqualone; 326
(c) Methaqualone; 327
(7) Any material, compound, mixture or preparation 328
containing any quantity of the following substances having a 329
stimulant effect on the central nervous system, including 330
their salts, isomers and salts of isomers: 331
(a) Aminorex; 332
(b) N-benzylpiperazine; 333
(c) Cathinone; 334
SB 1605 12
(d) Fenethylline; 335
(e) 3-Fluoromethcathinone; 336
(f) 4-Fluoromethcathinone; 337
(g) Mephedrone, or 4-methylmethcathinone; 338
(h) Methcathinone; 339
(i) 4-methoxymethcathinone; 340
(j) (+,-)cis-4-methylaminorex ((+,-)cis-4,5-dihydro-4- 341
methyl-5-phenyl-2-oxazolamine); 342
(k) Methylenedioxypyrovalerone, MDPV, or 1-(1,3- 343
Benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-pentanone; 344
(l) Methylone, or 3,4-Methylenedioxymethcathinone; 345
(m) 4-Methyl-alpha-pyrrolidinobutiophenone, or MPBP; 346
(n) N-ethylamphetamine; 347
(o) N,N-dimethylamphetamine; 348
(p) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB- 349
22; QUPIC); 350
(q) Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3- 351
carboxylate (5-fluoro-PB-22; 5F-PB-22); 352
(r) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4- 353
fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA); 354
(s) N-(1-amino-3, 3-dimethyl-1-oxobutan-2-yl)-1-pentyl- 355
1H-indazole-3-carboxamide (ADB-PINACA); 356
(8) A temporary listing of substances subject to 357
emergency scheduling under federal law shall include any 358
material, compound, mixture or preparation which contains 359
any quantity of the following substances: 360
(a) (1-pentyl-1H-indol-3-yl)(2,2,3,3- 361
tetramethylcyclopropyl)methanone, its optical, positional, 362
and geometric isomers, salts, and salts of isomers; 363
(b) [1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3- 364
tetramethylcyclopropyl)methanone, its optical, positional, 365
and geometric isomers, salts, and salts of isomers; 366
SB 1605 13
(c) N-(1-adamantyl)-1-pentyl-1H-indazole-3- 367
carboxamide, its optical, positional, and geometric isomers, 368
salts, and salts of isomers; 369
(d) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2- 370
methoxybenzyl)ethanamine, its optical, positional, and 371
geometric isomers, salts, and salts of isomers; 372
(e) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2- 373
methoxybenzyl)ethanamine, its optical, positional, and 374
geometric isomers, salts, and salts of isomers; 375
(f) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2- 376
methoxybenzyl)ethanamine, its optical, positional, and 377
geometric isomers, salts, and salts of isomers; 378
(g) 4-methyl-N-ethylcathinone, its optical, 379
positional, and geometric isomers, salts, and salts of 380
isomers; 381
(h) 4-methyl-alpha-pyrrolidinopropiophenone, its 382
optical, positional, and geometric isomers, salts, and salts 383
of isomers; 384
(i) Alpha-pyrrolidinopentiophenone, its optical, 385
positional, and geometric isomers, salts, and salts of 386
isomers; 387
(j) Butylone, its optical, positional, and geometric 388
isomers, salts, and salts of isomers; 389
(k) Pentedrone, its optical, positional, and geometric 390
isomers, salts, and salts of isomers; 391
(l) Pentylone, its optical, positional, and geometric 392
isomers, salts, and salts of isomers; 393
(m) Naphyrone, its optical, positional, and geometric 394
isomers, salts, and salts of isomers; 395
(n) Alpha-pyrrolidinobutiophenone, its optical, 396
positional, and geometric isomers, salts, and salts of 397
isomers; 398
SB 1605 14
(o) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1- 399
(cyclohexylmethyl)-1H-indazole-3-carboxamide, its optical, 400
positional, and geometric isomers, salts, and salts of 401
isomers; 402
(p) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H- 403
indazole-3-carboxamide, its optical, positional, and 404
geometric isomers, salts, and salts of isomers; 405
(q) [1-(5-fluoropentyl)-1H-indazole-3-yl](naphthalen-1- 406
yl)methanone, its optical, positional, and geometric 407
isomers, salts, and salts of isomers; 408
(r) N-[1-[2-hydroxy-2-(thiophen-2-yl) ethyl]piperidin- 409
4-yl]-N-phenylpropionamide, its isomers, esters, ethers, 410
salts, and salts of isomers, esters, and ethers; 411
(s) N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide, 412
its optical, positional, and geometric isomers, salts, and 413
salts of isomers; 414
(t) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1- 415
(cyclohexylmethyl)-1H-indazole-3-carboxamide, its optical, 416
positional, and geometric isomers, salts, and salts of 417
isomers; 418
(u) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3- 419
carboxamido)-3,3-dimethylbutanoate, its optical, positional, 420
and geometric isomers, salts, and salts of isomers; 421
(v) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3- 422
carboxamido)-3-methylbutanoate, its optical, positional, and 423
geometric isomers, salts, and salts of isomers; 424
(w) N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole- 425
3-carboxamide, its optical, positional, and geometric 426
isomers, salts, and salts of isomers; 427
(x) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4- 428
fluorobenzyl)-1H-indazole-3-carboxamide, its optical, 429
SB 1605 15
positional, and geometric isomers, salts, and salts of 430
isomers; 431
(y) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3- 432
carboxamido)-3,3-dimethylbutanoate, its optical, positional, 433
and geometric isomers, salts, and salts of isomers; 434
(z) methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3- 435
carboxamido)-3,3-dimethylbutanoate, its optical, positional, 436
and geometric isomers, salts, and salts of isomers; 437
(aa) N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4- 438
yl)propionamide, its isomers, esters, ethers, salts, and 439
salts of isomers, esters, and ethers; 440
(bb) methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3- 441
carboxamido)-3-methylbutanoate, its optical, positional, and 442
geometric isomers, salts, and salts of isomers; 443
(cc) N-(1-phenethylpiperidin-4-yl)-N- 444
phenylcyclopropanecarboxamide, its isomers, esters, ethers, 445
salts, and salts of isomers, esters, and ethers; 446
(dd) N-(1-phenethylpiperidin-4-yl)-N- 447
phenylpentanamide, its isomers, esters, ethers, salts, and 448
salts of isomers, esters, and ethers; 449
(ee) N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4- 450
yl)butyramide, its isomers, esters, ethers, salts, and salts 451
of isomers, esters, and ethers; 452
(ff) N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4- 453
yl)butyramide, its isomers, esters, ethers, salts, and salts 454
of isomers, esters, and ethers; 455
(gg) N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4- 456
yl)isobutyramide, its isomers, esters, ethers, salts, and 457
salts of isomers, esters, and ethers; 458
(hh) N-(1-phenethylpiperidin-4-yl)-N- 459
phenylisobutyramide, its isomers, esters, ethers, salts, and 460
salts of isomers, esters, and ethers; 461
SB 1605 16
(ii) N-(1-phenethylpiperidin-4-yl)-N- 462
phenylcyclopentanecarboxamide, its isomers, esters, ethers, 463
salts, and salts of isomers, esters, and ethers; 464
(jj) Fentanyl-related substances, their isomers, 465
esters, ethers, salts, and salts of isomers, esters, and 466
ethers. Fentanyl-related substance shall mean any substance 467
not otherwise listed under another Drug Enforcement 468
Administration Controlled Substance Code Number, and for 469
which no exemption or approval is in effect under section 470
505 of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 471
Section 355, that is structurally related to fentanyl by one 472
or more of the following modifications: 473
a. Replacement of the phenyl portion of the phenethyl 474
group by any monocycle, whether or not further substituted 475
in or on the monocycle; 476
b. Substitution in or on the phenethyl group with 477
alkyl, alkenyl, alkoxyl, hydroxyl, halo, haloalkyl, amino or 478
nitro groups; 479
c. Substitution in or on the piperidine ring with 480
alkyl, alkenyl, alkoxyl, ester, ether, hydroxyl, amino or 481
nitro groups; 482
d. Replacement of the aniline ring with any aromatic 483
monocycle, whether or not further substituted in or on the 484
aromatic monocycle; or 485
e. Replacement of the N-propionyl group by another 486
acyl group; 487
(kk) Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3- 488
carboxylate, its optical, positional, and geometric isomers, 489
salts, and salts of isomers (NM2201; CBL2201); 490
(ll) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5- 491
fluoropentyl)-1H-indazole-3-carboxamide, its optical, 492
SB 1605 17
positional, and geometric isomers, salts, and salts of 493
isomers (5F-AB-PINACA); 494
(mm) 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H- 495
indazole-3-carboxamide, its optical, positional, and 496
geometric isomers, salts, and salts of isomers (4-CN-CUMYL- 497
BUTINACA; 4-cyano-CUMYL-BUTINACA; 4-CN-CUMYLBINACA; CUMYL- 498
4CN-BINACA; SGT-78); 499
(nn) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3- 500
carboxamido)-3-methylbutanoate, its optical, positional, and 501
geometric isomers, salts, and salts of isomers (MMB-CHMICA, 502
AMB-CHMICA); 503
(oo) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H- 504
pyrrolo[2,3-b]pyridine-3-carboxamide, its optical, 505
positional, and geometric isomers, salts, and salts of 506
isomers (5F-CUMYL-P7AICA); 507
(pp) N-ethylpentylone, its optical, positional, and 508
geometric isomers, salts, and salts of isomers (ephylone, 1- 509
(1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one; 510
(qq) ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3- 511
carboxamido)-3,3-dimethylbutanoate, its optical, positional, 512
and geometric isomers, salts, and salts of isomers (trivial 513
name: 5F-EDMB-PINACA); 514
(rr) methyl 2-(1-(5-fluoropentyl)-1H-indole-3- 515
carboxamido)-3,3-dimethylbutanoate, its optical, positional, 516
and geometric isomers, salts, and salts of isomers (trivial 517
name: 5F-MDMB-PICA); 518
(ss) N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole- 519
3-carboxamide, its optical, positional, and geometric 520
isomers, salts, and salts of isomers (trivial names: FUB- 521
AKB48; FUB-APINACA; AKB48 N-(4-FLUOROBENZYL)); 522
(tt) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H- 523
indazole-3-carboxamide, its optical, positional, and 524
SB 1605 18
geometric isomers, salts, and salts of isomers (trivial 525
names: 5F-CUMYL-PINACA; SGT-25); 526
(uu) (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3- 527
tetramethylcyclopropyl) methanone, its optical, positional, 528
and geometric isomers, salts, and salts of isomers (trivial 529
name: FUB-144); 530
(vv) N-ethylhexedrone, its optical, positional, and 531
geometric isomers, salts, and salts of isomers (Other name: 532
2-(ethylamino)-1-phenylhexan-1-one); 533
(ww) alpha-pyrrolidinohexanophenone, its optical, 534
positional, and geometric isomers, salts, and salts of 535
isomers (Other names: α-PHP; alpha-pyrrolidinohexiophenone; 536
1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one); 537
(xx) 4-methyl-alpha-ethylaminopentiophenone, its 538
optical, positional, and geometric isomers, salts, and salts 539
of isomers; (Other names: 4-MEAP; 2-(ethylamino)-1-(4- 540
methylphenyl)pentan-1-one); 541
(yy) 4'-methyl-alpha-pyrrolidinohexiophenone, its 542
optical, positional, and geometric isomers, salts, and salts 543
of isomers (Other names: MPHP; 4'-methyl-alpha- 544
pyrrolidinohexanophenone; 1-(4-methylphenyl)-2-(pyrrolidin-1- 545
yl)hexan-1-one); 546
(zz) alpha-pyrrolidinoheptaphenone, its optical, 547
positional, and geometric isomers, salts, and salts of 548
isomers (Other names: PV8; 1-phenyl-2-(pyrrolidin-1- 549
yl)heptan-1-one); 550
(aaa) 4'-chloro-alpha-pyrrolidinovalerophenone, its 551
optical, positional, and geometric isomers, salts, and salts 552
of isomers (Other names: 4-chloro-α-PVP; 4'-chloro-alpha- 553
pyrrolidinopentiophenone; 1-(4-chlorophenyl)-2-(pyrrolidin-1- 554
yl)pentan-1-one); 555
SB 1605 19
(9) Khat, to include all parts of the plant presently 556
classified botanically as catha edulis, whether growing or 557
not; the seeds thereof; any extract from any part of such 558
plant; and every compound, manufacture, salt, derivative, 559
mixture, or preparation of the plant, its seed or extracts; 560
(10) 7-Hydroxymitragynine (methyl (E)-2- 561
[(2S,3S,7aS,12bS)-3-ethyl-7a-hydroxy-8-methoxy-2,3,4,6,7,12b- 562
hexahydro-1H-indolo[2,3-a]quinolizin-2-yl]-3-methoxyprop-2- 563
enoate) concentrated at a level above four hundred parts per 564
million on a dry-weight basis. 565
3. The department of health and senior services shall 566
place a substance in Schedule II if it finds that: 567
(1) The substance has high potential for abuse; 568
(2) The substance has currently accepted medical use 569
in treatment in the United States, or currently accepted 570
medical use with severe restrictions; and 571
(3) The abuse of the substance may lead to severe 572
psychic or physical dependence. 573
4. The controlled substances listed in this subsection 574
are included in Schedule II: 575
(1) Any of the following substances whether produced 576
directly or indirectly by extraction from substances of 577
vegetable origin, or independently by means of chemical 578
synthesis, or by combination of extraction and chemical 579
synthesis: 580
(a) Opium and opiate; and any salt, compound, 581
derivative or preparation of opium or opiate, excluding 582
apomorphine, thebaine-derived butorphanol, dextrorphan, 583
nalbuphine, nalmefene, naloxegol, naloxone, and naltrexone, 584
and their respective salts, but including the following: 585
a. Raw opium; 586
b. Opium extracts; 587
SB 1605 20
c. Opium fluid; 588
d. Powdered opium; 589
e. Granulated opium; 590
f. Tincture of opium; 591
g. Codeine; 592
h. Dihydroetorphine; 593
i. Ethylmorphine; 594
j. Etorphine hydrochloride; 595
k. Hydrocodone; 596
l. Hydromorphone; 597
m. Metopon; 598
n. Morphine; 599
o. Oripavine; 600
p. Oxycodone; 601
q. Oxymorphone; 602
r. Thebaine; 603
(b) Any salt, compound, derivative, or preparation 604
thereof which is chemically equivalent or identical with any 605
of the substances referred to in this subdivision, but not 606
including the isoquinoline alkaloids of opium; 607
(c) Opium poppy and poppy straw; 608
(d) Coca leaves and any salt, compound, derivative, or 609
preparation of coca leaves, and any salt, compound, 610
derivative, or preparation thereof which is chemically 611
equivalent or identical with any of these substances, but 612
not including the following: 613
a. Decocainized coca leaves or extractions of coca 614
leaves, which extractions do not contain cocaine or 615
ecgonine; or 616
b. Ioflupane; 617
SB 1605 21
(e) Concentrate of poppy straw (the crude extract of 618
poppy straw in either liquid, solid or powder form which 619
contains the phenanthrene alkaloids of the opium poppy); 620
(2) Any of the following opiates, including their 621
isomers, esters, ethers, salts, and salts of isomers, 622
whenever the existence of these isomers, esters, ethers, and 623
salts is possible within the specific chemical designation, 624
dextrorphan and levopropoxyphene excepted: 625
(a) Alfentanil; 626
(b) Alphaprodine; 627
(c) Anileridine; 628
(d) Bezitramide; 629
(e) Bulk dextropropoxyphene; 630
(f) Carfentanil; 631
(g) Dihydrocodeine; 632
(h) Diphenoxylate; 633
(i) Fentanyl; 634
(j) Isomethadone; 635
(k) Levo-alphacetylmethadol; 636
(l) Levomethorphan; 637
(m) Levorphanol; 638
(n) Metazocine; 639
(o) Methadone; 640
(p) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 641
4-diphenylbutane; 642
(q) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1- 643
diphenylpropane-carboxylic acid; 644
(r) Pethidine (meperidine); 645
(s) Pethidine-Intermediate-A, 4-cyano-1-methyl-4- 646
phenylpiperidine; 647
(t) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine- 648
4-carboxylate; 649
SB 1605 22
(u) Pethidine-Intermediate-C, 1-methyl-4- 650
phenylpiperdine-4-carboxylic acid; 651
(v) Phenazocine; 652
(w) Piminodine; 653
(x) Racemethorphan; 654
(y) Racemorphan; 655
(z) Remifentanil; 656
(aa) Sufentanil; 657
(bb) Tapentadol; 658
(cc) Thiafentanil; 659
(3) Any material, compound, mixture, or preparation 660
which contains any quantity of the following substances 661
having a stimulant effect on the central nervous system: 662
(a) Amphetamine, its salts, optical isomers, and salts 663
of its optical isomers; 664
(b) Lisdexamfetamine, its salts, isomers, and salts of 665
its isomers; 666
(c) Methamphetamine, its salts, isomers, and salts of 667
its isomers; 668
(d) Phenmetrazine and its salts; 669
(e) Methylphenidate; 670
(4) Any material, compound, mixture, or preparation 671
which contains any quantity of the following substances 672
having a depressant effect on the central nervous system, 673
including its salts, isomers, and salts of isomers whenever 674
the existence of those salts, isomers, and salts of isomers 675
is possible within the specific chemical designation: 676
(a) Amobarbital; 677
(b) Glutethimide; 678
(c) Pentobarbital; 679
(d) Phencyclidine; 680
(e) Secobarbital; 681
SB 1605 23
(5) Hallucinogenic substances: 682
(a) Any material or compound which contains any 683
quantity of nabilone; 684
(b) Dronabinol [(-)-Δ-9-trans tetrahydrocannabinol] in 685
an oral solution in a drug product approved for marketing by 686
the U.S. Food and Drug Administration; 687
(6) Any material, compound, mixture, or preparation 688
which contains any quantity of the following substances: 689
(a) Immediate precursor to amphetamine and 690
methamphetamine: Phenylacetone; 691
(b) Immediate precursors to phencyclidine (PCP): 692
a. 1-phenylcyclohexylamine; 693
b. 1-piperidinocyclohexanecarbonitrile (PCC); 694
(c) Immediate precursor to fentanyl: 4-anilino-N- 695
phenethyl-4-piperidine (ANPP); 696
(7) Any material, compound, mixture, or preparation 697
which contains any quantity of the following alkyl nitrites: 698
(a) Amyl nitrite; 699
(b) Butyl nitrite. 700
5. The department of health and senior services shall 701
place a substance in Schedule III if it finds that: 702
(1) The substance has a potential for abuse less than 703
the substances listed in Schedules I and II; 704
(2) The substance has currently accepted medical use 705
in treatment in the United States; and 706
(3) Abuse of the substance may lead to moderate or low 707
physical dependence or high psychological dependence. 708
6. The controlled substances listed in this subsection 709
are included in Schedule III: 710
(1) Any material, compound, mixture, or preparation 711
which contains any quantity of the following substances 712
SB 1605 24
having a potential for abuse associated with a stimulant 713
effect on the central nervous system: 714
(a) Benzphetamine; 715
(b) Chlorphentermine; 716
(c) Clortermine; 717
(d) Phendimetrazine; 718
(2) Any material, compound, mixture or preparation 719
which contains any quantity or salt of the following 720
substances or salts having a depressant effect on the 721
central nervous system: 722
(a) Any material, compound, mixture or preparation 723
which contains any quantity or salt of the following 724
substances combined with one or more active medicinal 725
ingredients: 726
a. Amobarbital; 727
b. Secobarbital; 728
c. Pentobarbital; 729
(b) Any suppository dosage form containing any 730
quantity or salt of the following: 731
a. Amobarbital; 732
b. Secobarbital; 733
c. Pentobarbital; 734
(c) Any substance which contains any quantity of a 735
derivative of barbituric acid or its salt; 736
(d) Chlorhexadol; 737
(e) Embutramide; 738
(f) Gamma hydroxybutyric acid and its salts, isomers, 739
and salts of isomers contained in a drug product for which 740
an application has been approved under Section 505 of the 741
federal Food, Drug, and Cosmetic Act; 742
(g) Ketamine, its salts, isomers, and salts of isomers; 743
(h) Lysergic acid; 744
SB 1605 25
(i) Lysergic acid amide; 745
(j) Methyprylon; 746
(k) Perampanel, and its salts, isomers, and salts of 747
isomers; 748
(l) Sulfondiethylmethane; 749
(m) Sulfonethylmethane; 750
(n) Sulfonmethane; 751
(o) Tiletamine and zolazepam or any salt thereof; 752
(3) Nalorphine; 753
(4) Any material, compound, mixture, or preparation 754
containing limited quantities of any of the following 755
narcotic drugs or their salts: 756
(a) Not more than 1.8 grams of codeine per one hundred 757
milliliters or not more than ninety milligrams per dosage 758
unit, with an equal or greater quantity of an isoquinoline 759
alkaloid of opium; 760
(b) Not more than 1.8 grams of codeine per one hundred 761
milliliters or not more than ninety milligrams per dosage 762
unit with one or more active, nonnarcotic ingredients in 763
recognized therapeutic amounts; 764
(c) Not more than 1.8 grams of dihydrocodeine per one 765
hundred milliliters or not more than ninety milligrams per 766
dosage unit, with one or more active, nonnarcotic 767
ingredients in recognized therapeutic amounts; 768
(d) Not more than three hundred milligrams of 769
ethylmorphine per one hundred milliliters or not more than 770
fifteen milligrams per dosage unit, with one or more active, 771
nonnarcotic ingredients in recognized therapeutic amounts; 772
(e) Not more than five hundred milligrams of opium per 773
one hundred milliliters or per one hundred grams or not more 774
than twenty-five milligrams per dosage unit, with one or 775
SB 1605 26
more active nonnarcotic ingredients in recognized 776
therapeutic amounts; 777
(f) Not more than fifty milligrams of morphine per one 778
hundred milliliters or per one hundred grams, with one or 779
more active, nonnarcotic ingredients in recognized 780
therapeutic amounts; 781
(5) Any material, compound, mixture, or preparation 782
containing any of the following narcotic drugs or their 783
salts: Buprenorphine; 784
(6) Anabolic steroids. Any drug or hormonal 785
substance, chemically and pharmacologically related to 786
testosterone (other than estrogens, progestins, 787
corticosteroids, and dehydroepiandrosterone) that promotes 788
muscle growth, except an anabolic steroid which is expressly 789
intended for administration through implants to cattle or 790
other nonhuman species and which has been approved by the 791
Secretary of Health and Human Services for that 792
administration. If any person prescribes, dispenses, or 793
distributes such steroid for human use, such person shall be 794
considered to have prescribed, dispensed, or distributed an 795
anabolic steroid within the meaning of this subdivision. 796
Unless specifically excepted or unless listed in another 797
schedule, any material, compound, mixture or preparation 798
containing any quantity of the following substances, 799
including its salts, esters and ethers: 800
(a) 3ß,17ß-dihydroxy-5α-androstane; 801
(b) 3α,17β-dihydroxy-5α-androstane; 802
(c) 5α-androstan-3,17-dione; 803
(d) 1-androstenediol (3β,17β-dihydroxy-5α-androst-1- 804
ene); 805
(e) 1-androstenediol (3α,17β-dihydroxy-5α-androst-1- 806
ene); 807
SB 1605 27
(f) 4-androstenediol (3β,17β-dihydroxy-androst-4-ene); 808
(g) 5-androstenediol (3β,17β-dihydroxy-androst-5-ene); 809
(h) 1-androstenedione ([5α]-androst-1-en-3,17-dione); 810
(i) 4-androstenedione (androst-4-en-3,17-dione); 811
(j) 5-androstenedione (androst-5-en-3,17-dione); 812
(k) Bolasterone (7α, 17α-dimethyl-17β-hydroxyandrost-4- 813
en-3-one); 814
(l) Boldenone (17β-hydroxyandrost-1,4,-diene-3-one); 815
(m) Boldione; 816
(n) Calusterone (7β, 17α-dimethyl-17β-hydroxyandrost-4- 817
en-3-one); 818
(o) Clostebol (4-chloro-17β-hydroxyandrost-4-en-3-one); 819
(p) Dehydrochloromethyltestosterone (4-chloro-17β- 820
hydroxy-17α-methyl-androst-1,4-dien-3-one); 821
(q) Desoxymethyltestosterone; 822
(r) 4-dihydrotestosterone (17ß-hydroxy-androstan-3- 823
one); 824
(s) Drostanolone (17ß-hydroxy-2α-methyl-5α-androstan-3- 825
one); 826
(t) Ethylestrenol (17α-ethyl-17ß-hydroxyestr-4-ene); 827
(u) Fluoxymesterone (9-fluoro-17α-methyl-11ß,17ß- 828
dihydroxyandrost-4-en-3-one); 829
(v) Formebolone (2-formyl-17α-methyl-11α,17ß- 830
dihydroxyandrost-1,4-dien-3-one); 831
(w) Furazabol (17α-methyl-17ß-hydroxyandrostano[2,3-c]- 832
furazan); 833
(x) 13ß-ethyl-17ß-hydroxygon-4-en-3-one; 834
(y) 4-hydroxytestosterone (4,17ß-dihydroxy-androst-4- 835
en-3-one); 836
(z) 4-hydroxy-19-nortestosterone (4,17ß-dihydroxy-estr- 837
4-en-3-one); 838
SB 1605 28
(aa) Mestanolone (17α-methyl-17ß-hydroxy-5α-androstan- 839
3-one); 840
(bb) Mesterolone (1α- methyl-17ß-hydroxy-[5α]- 841
androstan-3-one); 842
(cc) Methandienone (17α-methyl-17ß-hydroxyandrost-1,4- 843
dien-3-one); 844
(dd) Methandriol (17α-methyl-3ß,17ß-dihydroxyandrost-5- 845
ene); 846
(ee) Methasterone (2α,17α-dimethyl-5α-androstan-17β-ol- 847
3-one); 848
(ff) Methenolone (1-methyl-17ß-hydroxy-5α-androst-1-en- 849
3-one); 850
(gg) 17α-methyl-3β,17β-dihydroxy-5α-androstane; 851
(hh) 17α-methyl-3α,17β-dihydroxy-5α-androstane; 852
(ii) 17α-methyl-3β,17β-dihydroxyandrost-4-ene; 853
(jj) 17α-methyl-4-hydroxynandrolone (17α-methyl-4- 854
hydroxy-17β-hydroxyestr-4-en-3-one); 855
(kk) Methyldienolone (17α-methyl-17β-hydroxyestra- 856
4,9(10)-dien-3-one); 857
(ll) Methyltrienolone (17α-methyl-17β-hydroxyestra- 858
4,9,11-trien-3-one); 859
(mm) Methyltestosterone (17α-methyl-17β-hydroxyandrost- 860
4-en-3-one); 861
(nn) Mibolerone (7α,17α-dimethyl-17β-hydroxyestr-4-en- 862
3-one); 863
(oo) 17α-methyl-Δ1-dihydrotestosterone (17β-hydroxy- 864
17α-methyl-5α-androst-1-en-3-one) (a.k.a. '17-α-methyl-1- 865
testosterone'); 866
(pp) Nandrolone (17β-hydroxyestr-4-ene-3-one); 867
(qq) 19-nor-4-androstenediol (3β,17β-dihydroxyestr-4- 868
ene); 869
SB 1605 29
(rr) 19-nor-4-androstenediol (3α,17β-dihydroxyestr-4- 870
ene); 871
(ss) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)- 872
diene-3,17-dione); 873
(tt) 19-nor-5-androstenediol (3β,17β-dihydroxyestr-5- 874
ene); 875
(uu) 19-nor-5-androstenediol (3α,17β-dihydroxyestr-5- 876
ene); 877
(vv) 19-nor-4-androstenedione (estr-4-en-3,17-dione); 878
(ww) 19-nor-5-androstenedione (estr-5-en-3,17-dione); 879
(xx) Norbolethone (13β,17α-diethyl-17β-hydroxygon-4-en- 880
3-one); 881
(yy) Norclostebol (4-chloro-17β-hydroxyestr-4-en-3- 882
one); 883
(zz) Norethandrolone (17α-ethyl-17β-hydroxyestr-4-en-3- 884
one); 885
(aaa) Normethandrolone (17α-methyl-17β-hydroxyestr-4- 886
en-3-one); 887
(bbb) Oxandrolone (17α-methyl-17β-hydroxy-2-oxa-[5α]- 888
androstan-3-one); 889
(ccc) Oxymesterone (17α-methyl-4,17β-dihydroxyandrost- 890
4-en-3-one); 891
(ddd) metholone (17α-methyl-2-hydroxymethylene-17β- 892
hydroxy-[5α]-androstan-3-one); 893
(eee) Prostanozol (17β-hydroxy-5α-androstano[3,2- 894
c]pyrazole); 895
(fff) Stanolone (Δ1-dihydrotestosterone (a.k.a. 1- 896
testosterone)(17β-hydroxy-5α-androst-1-en-3-one)); 897
(ggg) Stanozolol (17α-methyl-17ß-hydroxy-[5α]-androst- 898
2-eno[3,2-c]-pyrazole); 899
(hhh) Stenbolone (17ß-hydroxy-2-methyl-[5α]-androst-1- 900
en-3-one); 901
SB 1605 30
(iii) Testolactone (13-hydroxy-3-oxo-13,17- 902
secoandrosta-1,4-dien-17-oic acid lactone); 903
(jjj) Testosterone (17ß-hydroxyandrost-4-en-3-one); 904
(kkk) Tetrahydrogestrinone (13ß,17α-diethyl-17ß- 905
hydroxygon-4,9,11-trien-3-one); 906
(lll) Trenbolone (17ß-hydroxyestr-4,9,11-trien-3-one); 907
(mmm) Any salt, ester, or ether of a drug or substance 908
described or listed in this subdivision, except an anabolic 909
steroid which is expressly intended for administration 910
through implants to cattle or other nonhuman species and 911
which has been approved by the Secretary of Health and Human 912
Services for that administration; 913
(7) Dronabinol (synthetic) in sesame oil and 914
encapsulated in a soft gelatin capsule in a United States 915
Food and Drug Administration approved drug product; 916
(8) The department of health and senior services may 917
except by rule any compound, mixture, or preparation 918
containing any stimulant or depressant substance listed in 919
subdivisions (1) and (2) of this subsection from the 920
application of all or any part of sections 195.010 to 921
195.320 if the compound, mixture, or preparation contains 922
one or more active medicinal ingredients not having a 923
stimulant or depressant effect on the central nervous 924
system, and if the admixtures are included therein in 925
combinations, quantity, proportion, or concentration that 926
vitiate the potential for abuse of the substances which have 927
a stimulant or depressant effect on the central nervous 928
system. 929
7. The department of health and senior services shall 930
place a substance in Schedule IV if it finds that: 931
(1) The substance has a low potential for abuse 932
relative to substances in Schedule III; 933
SB 1605 31
(2) The substance has currently accepted medical use 934
in treatment in the United States; and 935
(3) Abuse of the substance may lead to limited 936
physical dependence or psychological dependence relative to 937
the substances in Schedule III. 938
8. The controlled substances listed in this subsection 939
are included in Schedule IV: 940
(1) Any material, compound, mixture, or preparation 941
containing any of the following narcotic drugs or their 942
salts calculated as the free anhydrous base or alkaloid, in 943
limited quantities as set forth below: 944
(a) Not more than one milligram of difenoxin and not 945
less than twenty-five micrograms of atropine sulfate per 946
dosage unit; 947
(b) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2- 948
diphenyl-3-methyl-2-propionoxybutane); 949
(c) 2-[(dimethylamino)methyl]-1-(3- 950
methoxyphenyl)cyclohexanol, its salts, optical and geometric 951
isomers, and salts of these isomers (including tramadol); 952
(d) Any of the following limited quantities of 953
narcotic drugs or their salts, which shall include one or 954
more nonnarcotic active medicinal ingredients in sufficient 955
proportion to confer upon the compound, mixture or 956
preparation valuable medicinal qualities other than those 957
possessed by the narcotic drug alone: 958
a. Not more than two hundred milligrams of codeine per 959
one hundred milliliters or per one hundred grams; 960
b. Not more than one hundred milligrams of 961
dihydrocodeine per one hundred milliliters or per one 962
hundred grams; 963
SB 1605 32
c. Not more than one hundred milligrams of 964
ethylmorphine per one hundred milliliters or per one hundred 965
grams; 966
(2) Any material, compound, mixture or preparation 967
containing any quantity of the following substances, 968
including their salts, isomers, and salts of isomers 969
whenever the existence of those salts, isomers, and salts of 970
isomers is possible within the specific chemical designation: 971
(a) Alfaxalone; 972
(b) Alprazolam; 973
(c) Barbital; 974
(d) Bromazepam; 975
(e) Camazepam; 976
(f) Carisoprodol; 977
(g) Chloral betaine; 978
(h) Chloral hydrate; 979
(i) Chlordiazepoxide; 980
(j) Clobazam; 981
(k) Clonazepam; 982
(l) Clorazepate; 983
(m) Clotiazepam; 984
(n) Cloxazolam; 985
(o) Delorazepam; 986
(p) Diazepam; 987
(q) Dichloralphenazone; 988
(r) Estazolam; 989
(s) Ethchlorvynol; 990
(t) Ethinamate; 991
(u) Ethyl loflazepate; 992
(v) Fludiazepam; 993
(w) Flunitrazepam; 994
(x) Flurazepam; 995
SB 1605 33
(y) Fospropofol; 996
(z) Halazepam; 997
(aa) Haloxazolam; 998
(bb) Ketazolam; 999
(cc) Loprazolam; 1000
(dd) Lorazepam; 1001
(ee) Lormetazepam; 1002
(ff) Mebutamate; 1003
(gg) Medazepam; 1004
(hh) Meprobamate; 1005
(ii) Methohexital; 1006
(jj) Methylphenobarbital (mephobarbital); 1007
(kk) Midazolam; 1008
(ll) Nimetazepam; 1009
(mm) Nitrazepam; 1010
(nn) Nordiazepam; 1011
(oo) Oxazepam; 1012
(pp) Oxazolam; 1013
(qq) Paraldehyde; 1014
(rr) Petrichloral; 1015
(ss) Phenobarbital; 1016
(tt) Pinazepam; 1017
(uu) Prazepam; 1018
(vv) Quazepam; 1019
(ww) Suvorexant; 1020
(xx) Temazepam; 1021
(yy) Tetrazepam; 1022
(zz) Triazolam; 1023
(aaa) Zaleplon; 1024
(bbb) Zolpidem; 1025
(ccc) Zopiclone; 1026
SB 1605 34
(3) Any material, compound, mixture, or preparation 1027
which contains any quantity of the following substance 1028
including its salts, isomers and salts of isomers whenever 1029
the existence of such salts, isomers and salts of isomers is 1030
possible: fenfluramine; 1031
(4) Any material, compound, mixture, or preparation 1032
which contains any quantity of the following substances, 1033
including its salts, isomers, and salts of isomers, whenever 1034
the existence of such salts, isomers, and salts of isomers 1035
is possible: Lorcaserin; 1036
(5) Any material, compound, mixture or preparation 1037
containing any quantity of the following substances having a 1038
stimulant effect on the central nervous system, including 1039
their salts, isomers and salts of isomers: 1040
(a) Cathine ((+)-norpseudoephedrine); 1041
(b) Diethylpropion; 1042
(c) Fencamfamin; 1043
(d) Fenproporex; 1044
(e) Mazindol; 1045
(f) Mefenorex; 1046
(g) Modafinil; 1047
(h) Pemoline, including organometallic complexes and 1048
chelates thereof; 1049
(i) Phentermine; 1050
(j) Pipradrol; 1051
(k) Sibutramine; 1052
(l) SPA ((-)-1-dimethyamino-1,2-diphenylethane); 1053
(6) Any material, compound, mixture or preparation 1054
containing any quantity of the following substance, 1055
including its salts: 1056
(a) Butorphanol (including its optical isomers); 1057
SB 1605 35
(b) Eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl)- 1058
2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1 H- 1059
imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid) 1060
(including its optical isomers) and its salts, isomers, and 1061
salts of isomers; 1062
(c) Pentazocine; 1063
(7) Ephedrine, its salts, optical isomers and salts of 1064
optical isomers, when the substance is the only active 1065
medicinal ingredient; 1066
(8) The department of health and senior services may 1067
except by rule any compound, mixture, or preparation 1068
containing any depressant substance listed in subdivision 1069
(1) of this subsection from the application of all or any 1070
part of sections 195.010 to 195.320 and sections 579.015 to 1071
579.086 if the compound, mixture, or preparation contains 1072
one or more active medicinal ingredients not having a 1073
depressant effect on the central nervous system, and if the 1074
admixtures are included therein in combinations, quantity, 1075
proportion, or concentration that vitiate the potential for 1076
abuse of the substances which have a depressant effect on 1077
the central nervous system. 1078
9. The department of health and senior services shall 1079
place a substance in Schedule V if it finds that: 1080
(1) The substance has low potential for abuse relative 1081
to the controlled substances listed in Schedule IV; 1082
(2) The substance has currently accepted medical use 1083
in treatment in the United States; and 1084
(3) The substance has limited physical dependence or 1085
psychological dependence liability relative to the 1086
controlled substances listed in Schedule IV. 1087
10. The controlled substances listed in this 1088
subsection are included in Schedule V: 1089
SB 1605 36
(1) Any compound, mixture or preparation containing 1090
any of the following narcotic drugs or their salts 1091
calculated as the free anhydrous base or alkaloid, in 1092
limited quantities as set forth below, which also contains 1093
one or more nonnarcotic active medicinal ingredients in 1094
sufficient proportion to confer upon the compound, mixture 1095
or preparation valuable medicinal qualities other than those 1096
possessed by the narcotic drug alone: 1097
(a) Not more than two and five-tenths milligrams of 1098
diphenoxylate and not less than twenty-five micrograms of 1099
atropine sulfate per dosage unit; 1100
(b) Not more than one hundred milligrams of opium per 1101
one hundred milliliters or per one hundred grams; 1102
(c) Not more than five-tenths milligram of difenoxin 1103
and not less than twenty-five micrograms of atropine sulfate 1104
per dosage unit; 1105
(2) Any material, compound, mixture or preparation 1106
which contains any quantity of the following substance 1107
having a stimulant effect on the central nervous system 1108
including its salts, isomers and salts of isomers: 1109
pyrovalerone; 1110
(3) Any compound, mixture, or preparation containing 1111
any detectable quantity of pseudoephedrine or its salts or 1112
optical isomers, or salts of optical isomers or any 1113
compound, mixture, or preparation containing any detectable 1114
quantity of ephedrine or its salts or optical isomers, or 1115
salts of optical isomers; 1116
(4) Unless specifically exempted or excluded or unless 1117
listed in another schedule, any material, compound, mixture, 1118
or preparation which contains any quantity of the following 1119
substances having a depressant effect on the central nervous 1120
system, including its salts: 1121
SB 1605 37
(a) Brivaracetam ((25)-2-[(4R)-2-oxo-4- 1122
propylpyrrolidin-1-yl]butanamide) (also referred to as BRV; 1123
UCB-34714; Briviact); 1124
(b) Ezogabine [N-[2-amino-4(4-fluorobenzylamino)- 1125
phenyl]-carbamic acid ethyl ester]; 1126
(c) Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy- 1127
propionamide]; 1128
(d) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic 1129
acid]; 1130
(5) Any drug product in finished dosage formulation 1131
that has been approved by the U.S. Food and Drug 1132
Administration that contains cannabidiol (2-[1R-3-methyl-6R- 1133
(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3- 1134
benzenediol) derived from cannabis and no more than 0.1 1135
percent (w/w) residual tetrahydro cannabinols. 1136
11. If any compound, mixture, or preparation as 1137
specified in subdivision (3) of subsection 10 of this 1138
section is dispensed, sold, or distributed in a pharmacy 1139
without a prescription: 1140
(1) All packages of any compound, mixture, or 1141
preparation containing any detectable quantity of 1142
pseudoephedrine, its salts or optical isomers, or salts of 1143
optical isomers or ephedrine, its salts or optical isomers, 1144
or salts of optical isomers, shall be offered for sale only 1145
from behind a pharmacy counter where the public is not 1146
permitted, and only by a registered pharmacist or registered 1147
pharmacy technician; and 1148
(2) Any person purchasing, receiving or otherwise 1149
acquiring any compound, mixture, or preparation containing 1150
any detectable quantity of pseudoephedrine, its salts or 1151
optical isomers, or salts of optical isomers or ephedrine, 1152
SB 1605 38
its salts or optical isomers, or salts of optical isomers 1153
shall be at least eighteen years of age; and 1154
(3) The pharmacist, intern pharmacist, or registered 1155
pharmacy technician shall require any person, prior to such 1156
person's purchasing, receiving or otherwise acquiring such 1157
compound, mixture, or preparation to furnish suitable photo 1158
identification that is issued by a state or the federal 1159
government or a document that, with respect to 1160
identification, is considered acceptable and showing the 1161
date of birth of the person; 1162
(4) The seller shall deliver the product directly into 1163
the custody of the purchaser. 1164
12. Pharmacists, intern pharmacists, and registered 1165
pharmacy technicians shall implement and maintain an 1166
electronic log of each transaction. Such log shall include 1167
the following information: 1168
(1) The name, address, and signature of the purchaser; 1169
(2) The amount of the compound, mixture, or 1170
preparation purchased; 1171
(3) The date and time of each purchase; and 1172
(4) The name or initials of the pharmacist, intern 1173
pharmacist, or registered pharmacy technician who dispensed 1174
the compound, mixture, or preparation to the purchaser. 1175
13. Each pharmacy shall submit information regarding 1176
sales of any compound, mixture, or preparation as specified 1177
in subdivision (3) of subsection 10 of this section in 1178
accordance with transmission methods and frequency 1179
established by the department by regulation; 1180
14. No person shall dispense, sell, purchase, receive, 1181
or otherwise acquire quantities greater than those specified 1182
in this chapter. 1183
SB 1605 39
15. All persons who dispense or offer for sale 1184
pseudoephedrine and ephedrine products in a pharmacy shall 1185
ensure that all such products are located only behind a 1186
pharmacy counter where the public is not permitted. 1187
16. The penalties for a knowing or reckless violation 1188
of the provisions of subsections 11 to 15 of this section 1189
are found in section 579.060. 1190
17. The scheduling of substances specified in 1191
subdivision (3) of subsection 10 of this section and 1192
subsections 11, 12, 14, and 15 of this section shall not 1193
apply to any compounds, mixtures, or preparations that are 1194
in liquid or liquid-filled gel capsule form or to any 1195
compound, mixture, or preparation specified in subdivision 1196
(3) of subsection 10 of this section which must be 1197
dispensed, sold, or distributed in a pharmacy pursuant to a 1198
prescription. 1199
18. The manufacturer of a drug product or another 1200
interested party may apply with the department of health and 1201
senior services for an exemption from this section. The 1202
department of health and senior services may grant an 1203
exemption by rule from this section if the department finds 1204
the drug product is not used in the illegal manufacture of 1205
methamphetamine or other controlled or dangerous 1206
substances. The department of health and senior services 1207
shall rely on reports from law enforcement and law 1208
enforcement evidentiary laboratories in determining if the 1209
proposed product can be used to manufacture illicit 1210
controlled substances. 1211
19. The department of health and senior services shall 1212
revise and republish the schedules annually. 1213
20. The department of health and senior services shall 1214
promulgate rules under chapter 536 regarding the security 1215
SB 1605 40
and storage of Schedule V controlled substances, as 1216
described in subdivision (3) of subsection 10 of this 1217
section, for distributors as registered by the department of 1218
health and senior services. 1219
21. Logs of transactions required to be kept and 1220
maintained by this section and section 195.417 shall create 1221
a rebuttable presumption that the person whose name appears 1222
in the logs is the person whose transactions are recorded in 1223
the logs. 1224
✓